{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:12:49Z","timestamp":1792843969747,"version":"4.5.0"},"reference-count":138,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King Saud University, Riyadh, Saudi Arabia","award":["RSP2024R658"],"award-info":[{"award-number":["RSP2024R658"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Malaria is still one of the major global health challenges affecting millions annually, particularly in non-Mediterranean Africa and Southeast Asia. Over the past two decades, substantial progress has been made in reducing malaria-related morbidity and mortality, primarily due to advancements in antimalarial therapeutics. This review provides a comprehensive overview of recent developments in malaria treatment, focusing on the evolution of drug therapies, mechanisms of action, and emerging resistance patterns. The cornerstone of current treatment strategies is artemisinin-based combination therapies (ACTs), which have proven highly effective against P. falciparum and P. vivax, the most prevalent malaria-causing parasites. However, the onset of artemisinin resistance, particularly in Southeast Asian countries, poses a significant threat to these gains. Additionally, other antimalarial classes, including quinine derivatives, 8-aminoquinolines, and antifolate drugs, are examined for their efficacy, resistance mechanisms, and future potential. This review also discusses the challenges associated with drug resistance, the genetic underpinnings of resistance in malaria parasites, and the implications for future treatment protocols. Furthermore, the review examines combinational therapies, such as triple artemisinin combination therapies (TACTs), and vaccines that are approved or in development to circumvent resistance issues. The need for continuous surveillance, innovative therapeutic strategies, and advances in novel antimalarial therapeutic agents is emphasized to sustain and further progress in the control of malaria and its eventual eradication.<\/jats:p>","DOI":"10.3390\/pharmaceutics16111416","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:52:54Z","timestamp":1730713974000},"page":"1416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Recent Advances in the Treatment of Malaria"],"prefix":"10.3390","volume":"16","author":[{"given":"Jawaher M.","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Department of Zoology, College of Science, King Saud University, Riyadh 13242, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa A.","family":"Al-Qahtani","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University, Riyadh 11432, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1765-4310","authenticated-orcid":false,"given":"Fatimah S.","family":"Alhamlan","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia"},{"name":"Department of Microbiology and Immunology, College of Medicine, Alfaisal University, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4584-5739","authenticated-orcid":false,"given":"Ahmed A.","family":"Al-Qahtani","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunity, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia"},{"name":"Department of Microbiology and Immunology, College of Medicine, Alfaisal University, Riyadh 11211, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Al-Awadhi, M., Ahmad, S., and Iqbal, J. (2021). Current Status and the Epidemiology of Malaria in the Middle East Region and Beyond. Microorganisms, 9.","DOI":"10.3390\/microorganisms9020338"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Aliyo, A., Golicha, W., and Fikrie, A. (2024). Malaria and associated factors among under-five children in Borena pastoral communities, southern Ethiopia. Front. Parasitol., 3.","DOI":"10.3389\/fpara.2024.1438218"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Tarique, M. (2024). Introduction: An Overview of Malaria and Plasmodium. Drug Targets for Plasmodium falciparum: Historic to Future Perspectives, Springer Nature.","DOI":"10.1007\/978-981-19-4484-0"},{"key":"ref_4","unstructured":"Zekar, L., and Sharman, T. (2024, August 10). Plasmodium falciparum Malaria, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555962\/."},{"key":"ref_5","first-page":"395","article-title":"Update on malaria","volume":"155","author":"Varo","year":"2020","journal-title":"Med. Cl\u00ednica Engl. Ed."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kotepui, M., Kotepui, K.U., Milanez, G.D.J., and Masangkay, F.R. (2020). Prevalence and risk factors related to poor outcome of patients with severe Plasmodium vivax infection: A systematic review, meta-analysis, and analysis of case reports. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05046-y"},{"key":"ref_7","first-page":"3","article-title":"Plasmodium knowlesi-mediated zoonotic malaria: A challenge for elimination","volume":"10","author":"Naik","year":"2020","journal-title":"Trop. Parasitol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/1040841X.2020.1838440","article-title":"Plasmodium malariae, current knowledge and future research opportunities on a neglected malaria parasite species","volume":"47","author":"Oriero","year":"2021","journal-title":"Crit. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Patrick, G.L. (2020). Chapter 1\u2014History of malaria and its treatment. Antimalarial Agents, Elsevier.","DOI":"10.1016\/B978-0-08-101210-9.00001-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/QCO.0000000000000766","article-title":"Artemisinin and multidrug-resistant Plasmodium falciparum\u2014A threat for malaria control and elimination","volume":"34","author":"Dhorda","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","article-title":"Antimalarial drug discovery: Progress and approaches","volume":"22","author":"Wicht","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5060665","DOI":"10.1155\/2023\/5060665","article-title":"Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery\u2014An Update","volume":"2023","author":"Pandey","year":"2023","journal-title":"Adv. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.2147\/IDR.S279433","article-title":"Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery","volume":"13","author":"Shibeshi","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/cmdc.202000895","article-title":"Malaria Pigment Crystals: The Achilles\u2032 Heel of the Malaria Parasite","volume":"16","author":"Kapishnikov","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Biswas, P., Roy, R., Ghosh, K., Nath, D., Samadder, A., and Nandi, S. (2024). To quest new targets of Plasmodium parasite and their potential inhibitors to combat antimalarial drug resistance. J. Parasit. Dis.","DOI":"10.1007\/s12639-024-01687-x"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Wilkins, C.A., du Plessis, L.H., and Viljoen, J.M. (2021). Investigating In Vitro and Ex Vivo Properties of Artemether\/Lumefantrine Double-Fixed Dose Combination Lipid Matrix Tablets Prepared by Hot Fusion. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13070922"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpddr.2020.12.004","article-title":"Primaquine for Plasmodium vivax radical cure: What we do not know and why it matters","volume":"15","author":"Popovici","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Capela, R., Moreira, R., and Lopes, F. (2019). An Overview of Drug Resistance in Protozoal Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20225748"},{"key":"ref_19","first-page":"73","article-title":"A Review on Synthesis of Quinoline Analogs as Antimalarial, Antibacterial and Anticancer agents","volume":"8","author":"Yadessa","year":"2021","journal-title":"Ethiop. J. Sci. Sustain. Dev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMoa2104226","article-title":"Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria","volume":"386","author":"Negreiros","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bcp.14474","article-title":"Advances and roadblocks in the treatment of malaria","volume":"88","author":"Hanboonkunupakarn","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","article-title":"Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria","volume":"380","author":"Lacerda","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/cid\/ciab610","article-title":"Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area","volume":"74","author":"Wyss","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/milmed\/usz304","article-title":"Army Antimalarial Drug Development: An Advanced Development Case Study for Tafenoquine","volume":"185","author":"Zottig","year":"2020","journal-title":"Mil. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e01538-21","DOI":"10.1128\/aac.01538-21","article-title":"New Insights into Antimalarial Chemopreventive Activity of Antifolates","volume":"66","author":"Pethrak","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/aasopenres.12825.1","article-title":"Prevalence of chloroquine and antifolate drug resistance alleles in Plasmodium falciparum clinical isolates from three areas in Ghana","volume":"1","author":"Abugri","year":"2018","journal-title":"AAS Open Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1007\/s11033-022-07266-8","article-title":"Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: Successful targets against some infectious diseases","volume":"49","author":"Shamshad","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/0929867330666230310091510","article-title":"Dihydrofolate Reductase (DHFR) Inhibitors: A Comprehensive Review","volume":"31","author":"Sehrawat","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/jac\/dkl104","article-title":"The past, present and future of antifolates in the treatment of Plasmodium falciparum infection","volume":"57","author":"Nzila","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12936-024-04945-8","article-title":"Therapeutic efficacy and tolerability of artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria in Niger, 2020","volume":"23","author":"Laminou","year":"2024","journal-title":"Malar. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101829","DOI":"10.1016\/j.tmaid.2020.101829","article-title":"Atovaquone-proguanil treatment failure in a case of pediatric Plasmodium falciparum infection: Malabsorption and resistance","volume":"37","author":"Lau","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kurup, N., and Rajnani, N. (2022). Chronology of Drug Development for Malaria. Drug Development for Malaria, John Wiley & Sons, Ltd.","DOI":"10.1002\/9783527830589.ch1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2100338","DOI":"10.1002\/ardp.202100338","article-title":"Antiprotozoal agents: How have they changed over a decade?","volume":"355","author":"Fernandes","year":"2022","journal-title":"Arch. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/tmi.12352","article-title":"Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: Systematic review and meta-analysis","volume":"19","author":"Mbeye","year":"2014","journal-title":"Trop. Med. Int. Health TM IH"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Egwu, C.O., Augereau, J.-M., Reybier, K., and Benoit-Vical, F. (2021). Reactive Oxygen Species as the Brainbox in Malaria Treatment. Antioxidants, 10.","DOI":"10.3390\/antiox10121872"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.freeradbiomed.2021.03.001","article-title":"Superoxide: A major role in the mechanism of action of essential antimalarial drugs","volume":"167","author":"Egwu","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/med.21804","article-title":"The emerging paradigm of calcium homeostasis as a new therapeutic target for protozoan parasites","volume":"42","author":"Gupta","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jpha.2020.07.005","article-title":"Protecting future antimalarials from the trap of resistance: Lessons from artemisinin-based combination therapy (ACT) failures","volume":"11","author":"Erhunse","year":"2021","journal-title":"J. Pharm. Anal."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev-micro-020518-115546","article-title":"Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria","volume":"74","author":"Wicht","year":"2020","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7371681","DOI":"10.1155\/2020\/7371681","article-title":"Therapeutic Efficacy of Artemether-Lumefantrine (Coartem\u00ae) for the Treatment of Uncomplicated Falciparum Malaria in Africa: A Systematic Review","volume":"2020","author":"Derbie","year":"2020","journal-title":"J. Parasitol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12936-020-03520-1","article-title":"Asymptomatic recrudescence after artemether\u2013lumefantrine treatment for uncomplicated falciparum malaria: A systematic review and meta-analysis","volume":"19","author":"Mumtaz","year":"2020","journal-title":"Malar. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4269\/ajtmh.2009.80.126","article-title":"Does Artesunate Prolong the Electrocardiograph QT Interval in Patients with Severe Malaria?","volume":"80","author":"Maude","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Marwa, K., Kapesa, A., Baraka, V., Konje, E., Kidenya, B., Mukonzo, J., Kamugisha, E., and Swedberg, G. (2022). Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264339"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1475-2875-13-114","article-title":"Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999\u20132009","volume":"13","author":"Zwang","year":"2014","journal-title":"Malar. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12936-022-04380-7","article-title":"Therapeutic efficacy of dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium vivax malaria in Seacha area, Arbaminch Zuria District, South West Ethiopia","volume":"21","author":"Mohammed","year":"2022","journal-title":"Malar. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid2408.170768","article-title":"Therapeutic and Transmission-Blocking Efficacy of Dihydroartemisinin\/Piperaquine and Chloroquine against Plasmodium vivax Malaria, Cambodia","volume":"24","author":"Popovici","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Carrara, V.I., Sirilak, S., Thonglairuam, J., Rojanawatsirivet, C., Proux, S., Gilbos, V., Brockman, A., Ashley, E.A., McGready, R., and Krudsood, S. (2006). Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: The Tak Malaria Initiative. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030183"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0140-6736(00)02505-8","article-title":"Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study","volume":"356","author":"Nosten","year":"2000","journal-title":"Lancet Lond. Engl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin Resistance in Plasmodium falciparum Malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0035-9203(95)90094-2","article-title":"Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria","volume":"89","author":"Price","year":"1995","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1473-3099(16)30020-2","article-title":"Comparison of artesunate\u2013mefloquine and artemether\u2013lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: A randomised, multicentre, phase 4 trial","volume":"16","author":"Sirima","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lee, S.J., ter Kuile, F.O., Price, R.N., Luxemburger, C., and Nosten, F. (2017). Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19,850 individual patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0168780"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2147\/DDDT.S265602","article-title":"Recent Progress in the Development of New Antimalarial Drugs with Novel Targets","volume":"14","author":"Belete","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_54","first-page":"950424","article-title":"Role of Different Pfcrt and Pfmdr-1 Mutations in Conferring Resistance to Antimalaria Drugs in Plasmodium falciparum","volume":"2014","author":"Ibraheem","year":"2014","journal-title":"Malar. Res. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40794-022-00185-3","article-title":"Plasmodium vivax: The potential obstacles it presents to malaria elimination and eradication","volume":"8","author":"Habtamu","year":"2022","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_56","first-page":"90","article-title":"Current Medicines for Malaria Including Resistance Issues","volume":"11","author":"Nureye","year":"2020","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e01610-22","DOI":"10.1128\/aac.01610-22","article-title":"No Association between the Plasmodium vivax crt-o MS334 or In9pvcrt Polymorphisms and Chloroquine Failure in a Pre-Elimination Clinical Cohort from Malaysia with a Large Clonal Expansion","volume":"67","author":"Rumaseb","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1128\/AAC.00004-09","article-title":"Analysis of Single-Nucleotide Polymorphisms in the crt-o and mdr1 Genes of Plasmodium vivax among Chloroquine-Resistant Isolates from the Brazilian Amazon Region","volume":"53","author":"Chehuan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4269\/ajtmh.2007.76.245","article-title":"In Vitro Antimalarial Drug Susceptibility and Pfcrt Mutation Among Fresh Plasmodium falciparum Isolates from the Lao PDR (Laos)","volume":"76","author":"Mayxay","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1128\/AAC.00263-07","article-title":"In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: A synopsis of continuous assessment from 1994 to 2005","volume":"52","author":"Legrand","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ogetii, G.N., Akech, S., Jemutai, J., Boga, M., Kivaya, E., Fegan, G., and Maitland, K. (2010). Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage. BMC Infect. Dis., 10.","DOI":"10.1186\/1471-2334-10-334"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1128\/AAC.06396-11","article-title":"High Risk of QT Interval Prolongation and Torsades de Pointes Associated with Intravenous Quinidine Used for Treatment of Resistant Malaria or Babesiosis","volume":"56","author":"Wroblewski","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1128\/AAC.00060-08","article-title":"In vitro activity of ferroquine is independent of polymorphisms in transport protein genes implicated in quinoline resistance in Plasmodium falciparum","volume":"52","author":"Henry","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2125.1987.tb03020.x","article-title":"Pharmacokinetics of intravenous amodiaquine","volume":"23","author":"White","year":"1987","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, Double-Blind Study of the Safety, Tolerability, and Efficacy of Tafenoquine versus Mefloquine for Malaria Prophylaxis in Nonimmune Subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","unstructured":"Price, R.N., Simpson, J.A., and McCarthy, J.S. (2017). Halofantrine. Kucers\u2019 the Use of Antibiotics, CRC Press. [7th ed.]."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e01848-19","DOI":"10.1128\/AAC.01848-19","article-title":"Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria","volume":"64","author":"Wattanakul","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00303-17","DOI":"10.1128\/mBio.00303-17","article-title":"A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine","volume":"8","author":"Dhingra","year":"2017","journal-title":"mBio"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1345\/aph.1Q539","article-title":"Artemether-Lumefantrine: An Option for Malaria","volume":"46","author":"Stover","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/1475-2875-13-418","article-title":"Primaquine: The risks and the benefits","volume":"13","author":"Ashley","year":"2014","journal-title":"Malar. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tox.2012.01.015","article-title":"Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: Evaluation of eryptotic pathway","volume":"294","author":"Ganesan","year":"2012","journal-title":"Toxicology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s40265-018-0979-2","article-title":"Tafenoquine: First Global Approval","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e01370-17","DOI":"10.1128\/AAC.01370-17","article-title":"Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: A Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria","volume":"62","author":"Tarning","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2125.1993.tb04197.x","article-title":"The multiple dose pharmacokinetics of proguanil","volume":"35","author":"Helsby","year":"1993","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000238581","article-title":"Pharmacokinetics of Chlorproguanil in Man after a Single Oral Dose of Lapudrine\u00ae","volume":"34","author":"Veenendaal","year":"2009","journal-title":"Chemotherapy"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<245::AID-BDD99>3.0.CO;2-Z","article-title":"Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses","volume":"19","author":"Ashton","year":"1998","journal-title":"Biopharm. Drug Dispos."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s12936-016-1572-3","article-title":"Failure of dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in a traveller coming from Ethiopia","volume":"15","author":"Gobbi","year":"2016","journal-title":"Malar. J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Naing, C., Racloz, V., Whittaker, M.A., Aung, K., Reid, S.A., Mak, J.W., and Tanner, M. (2013). Efficacy and Safety of Dihydroartemisinin-Piperaquine for Treatment of Plasmodium vivax Malaria in Endemic Countries: Meta-Analysis of Randomized Controlled Studies. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078819"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Li, J., Zhang, J., Li, Q., Hu, Y., Ruan, Y., Tao, Z., Xia, H., Qiao, J., Meng, L., and Zeng, W. (2020). Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvmdr1 and Pvcrt-o genes. PLoS Negl. Trop. Dis., 14.","DOI":"10.1371\/journal.pntd.0008255"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sridapan, T., Rattanakoch, P., Kijprasong, K., and Srisutham, S. (2024). Drug resistance markers in Plasmodium vivax isolates from a Kanchanaburi province, Thailand between January to May 2023. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0304337"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.01135-09","article-title":"In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A\u2212) Individuals","volume":"54","author":"Shekalaghe","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S1368-7646(98)80014-9","article-title":"P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: Epidemiology and role in clinical resistance to antifolates","volume":"1","author":"Plowe","year":"1998","journal-title":"Drug Resist. Updat."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Nair, S., Miller, B., Barends, M., Jaidee, A., Patel, J., Mayxay, M., Newton, P., Nosten, F., Ferdig, M.T., and Anderson, T.J.C. (2008). Adaptive Copy Number Evolution in Malaria Parasites. PLOS Genet., 4.","DOI":"10.1371\/journal.pgen.1000243"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Kidgell, C., Volkman, S.K., Daily, J., Borevitz, J.O., Plouffe, D., Zhou, Y., Johnson, J.R., Roch, K.G.L., Sarr, O., and Ndir, O. (2006). A Systematic Map of Genetic Variation in Plasmodium falciparum. PLoS Pathog., 2.","DOI":"10.1371\/journal.ppat.0020096"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/bfgp\/elz008","article-title":"The genomic architecture of antimalarial drug resistance","volume":"18","author":"Cowell","year":"2019","journal-title":"Brief. Funct. Genom."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of Artemisinin Resistance in Plasmodium falciparum Malaria","volume":"371","author":"Ashley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1021\/acsinfecdis.9b00527","article-title":"Plasmodium falciparum Artemisinin Resistance: The Effect of Heme, Protein Damage, and Parasite Cell Stress Response","volume":"6","author":"Rosenthal","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12936-022-04385-2","article-title":"Drug resistance of Plasmodium falciparum and Plasmodium vivax isolates in Indonesia","volume":"21","author":"Rahmasari","year":"2022","journal-title":"Malar. J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1586\/14787210.2015.1052793","article-title":"The emerging threat of artemisinin resistance in malaria: Focus on artemether-lumefantrine","volume":"13","author":"Djimde","year":"2015","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijpddr.2020.10.009","article-title":"Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross","volume":"14","author":"Windle","year":"2020","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/ciy364","article-title":"Large-scale Artemisinin\u2013Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa","volume":"67","author":"Deng","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)30552-3","article-title":"Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: A multicentre, open-label, randomised clinical trial","volume":"395","author":"Tripura","year":"2020","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine","volume":"9","author":"Ross","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4269\/ajtmh.16-0234","article-title":"Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia","volume":"95","author":"Duru","year":"2016","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","article-title":"Current and emerging strategies to combat antimalarial resistance","volume":"20","author":"Rasmussen","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"104366","DOI":"10.1016\/j.amsu.2022.104366","article-title":"Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers","volume":"81","author":"Oladipo","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/acsinfecdis.3c00332","article-title":"Advancements and Challenges in Developing Malaria Vaccines: Targeting Multiple Stages of the Parasite Life Cycle","volume":"9","author":"Rajneesh","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apar.2015.03.001","article-title":"Chapter One\u2014Recent Developments in Malaria Vaccinology","volume":"Volume 88","author":"Rollinson","year":"2015","journal-title":"Advances in Parasitology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1146\/annurev.micro.091208.073403","article-title":"Malaria Parasite Development in the Mosquito and Infection of the Mammalian Host","volume":"63","author":"Aly","year":"2009","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Nunes-Caba\u00e7o, H., Moita, D., and Prud\u00eancio, M. (2022). Five decades of clinical assessment of whole-sporozoite malaria vaccines. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.977472"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"B233","DOI":"10.1016\/j.vaccine.2013.02.040","article-title":"Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities","volume":"31","author":"Birkett","year":"2013","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity","volume":"334","author":"Epstein","year":"2011","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/339409","article-title":"Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites","volume":"185","author":"Hoffman","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eaad9099","DOI":"10.1126\/scitranslmed.aad9099","article-title":"Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects","volume":"9","author":"Kublin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/hv.6.1.9654","article-title":"Genetically engineered, attenuated whole-cell vaccine approaches for malaria","volume":"6","author":"Vaughan","year":"2010","journal-title":"Hum. Vaccin."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.it.2012.02.001","article-title":"Whole parasite vaccination approaches for prevention of malaria infection","volume":"33","author":"Butler","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Malaria Vaccines: Progress to Date","volume":"37","author":"Stanisic","year":"2023","journal-title":"Biodrugs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40267-022-00937-3","article-title":"RTS,S\/AS01 malaria vaccine (Mosquirix\u00ae): A profile of its use","volume":"38","author":"Syed","year":"2022","journal-title":"Drugs Ther. Perspect."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (Mosquirix\u2122): An overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1590\/s1678-9946202163011","article-title":"Circumsporozoite Surface Protein-based malaria vaccines: A review","volume":"63","year":"2021","journal-title":"Rev. Inst. Med. Trop. S\u00e3o Paulo"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2189885","DOI":"10.1080\/21645515.2023.2189885","article-title":"The Matrix-M\u2122 adjuvant: A critical component of vaccines for the 21st century","volume":"19","author":"Stertman","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet Lond. Engl."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"450","DOI":"10.12688\/wellcomeopenres.19795.1","article-title":"Safety and immunogenicity of varied doses of R21\/Matrix-M\u2122 vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya","volume":"8","author":"Sang","year":"2023","journal-title":"Wellcome Open Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine","volume":"373","author":"Neafsey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Su, X., Zhang, C., and Joy, D.A. (2020). Host-Malaria Parasite Interactions and Impacts on Mutual Evolution. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.587933"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40794-024-00222-3","article-title":"A landscape review of malaria vaccine candidates in the pipeline","volume":"10","author":"Tajudeen","year":"2024","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Duffy, P.E. (2022). Current approaches to malaria vaccines. Curr. Opin. Microbiol., 70.","DOI":"10.1016\/j.mib.2022.102227"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/imr.12798","article-title":"Differentiation and adaptation of natural killer cells for anti-malarial immunity","volume":"293","author":"Goodier","year":"2020","journal-title":"Immunol. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Patarroyo, M.A., Molina-Franky, J., G\u00f3mez, M., Ar\u00e9valo-Pinz\u00f3n, G., and Patarroyo, M.E. (2020). Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134729"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pt.2007.10.004","article-title":"Targeting the Plasmodium vivax Duffy-binding protein","volume":"24","author":"Chitnis","year":"2008","journal-title":"Trends Parasitol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Weiss, G.E., Traore, B., Kayentao, K., Ongoiba, A., Doumbo, S., Doumtabe, D., Kone, Y., Dia, S., Guindo, A., and Traore, A. (2010). The Plasmodium falciparum-Specific Human Memory B Cell Compartment Expands Gradually with Repeated Malaria Infections. PLOS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000912"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(13)60024-0","article-title":"Malaria","volume":"383","author":"White","year":"2014","journal-title":"Lancet Lond. Engl."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","article-title":"Global malaria mortality between 1980 and 2010: A systematic analysis","volume":"379","author":"Murray","year":"2012","journal-title":"Lancet Lond. Engl."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Acharya, P., Garg, M., Kumar, P., Munjal, A., and Raja, K.D. (2017). Host\u2013Parasite Interactions in Human Malaria: Clinical Implications of Basic Research. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00889"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Frimpong, A., Kusi, K.A., Ofori, M.F., and Ndifon, W. (2018). Novel Strategies for Malaria Vaccine Design. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02769"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Kogan, F. (2020). Malaria Burden. Remote Sensing for Malaria: Monitoring and Predicting Malaria from Operational Satellites, Springer International Publishing.","DOI":"10.1007\/978-3-030-46020-4"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/ciw001","article-title":"Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges","volume":"62","author":"Roberts","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12936-017-2005-7","article-title":"Malaria case management by community health workers in the Central African Republic from 2009\u20132014: Overcoming challenges of access and instability due to conflict","volume":"16","author":"Ruckstuhl","year":"2017","journal-title":"Malar. J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s41745-021-00235-3","article-title":"Ecology and Evolution of Avian Malaria: Implications of Land Use Changes and Climate Change on Disease Dynamics","volume":"101","author":"Ishtiaq","year":"2021","journal-title":"J. Indian Inst. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13073-019-0673-3","article-title":"Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections","volume":"11","author":"Cowell","year":"2019","journal-title":"Genome Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.mib.2020.06.004","article-title":"The antimalarial resistome\u2014Finding new drug targets and their modes of action","volume":"57","author":"Carolino","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e12795","DOI":"10.1111\/pim.12795","article-title":"Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development","volume":"43","author":"Abuga","year":"2021","journal-title":"Parasite Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Stutzer, C., Richards, S.A., Ferreira, M., Baron, S., and Maritz-Olivier, C. (2018). Metazoan Parasite Vaccines: Present Status and Future Prospects. Front. Cell. Infect. Microbiol., 8.","DOI":"10.3389\/fcimb.2018.00067"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41541-022-00558-x","article-title":"Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver","volume":"7","author":"Geurten","year":"2022","journal-title":"Npj Vaccines"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1080\/23299460.2017.1419410","article-title":"Gene drive to reduce malaria transmission in sub-Saharan Africa","volume":"5","author":"Burt","year":"2018","journal-title":"J. Responsible Innov."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1416\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:26Z","timestamp":1760113706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/11\/1416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":138,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pharmaceutics16111416"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16111416","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}